Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma

Abstract

Although some patients had durable disease control, the addition of vorinostat to sorafenib led to toxicities in most patients, requiring dose modifications that prevented determination of the recommended phase 2 dose. The combination is not recommended for further exploration with this vorinostat schedule in this patient population.